
FDA approved Aurinia Pharmaceuticals LUPKYNIS (voclosporin) for adults with active lupus nephritis
On Jan. 22, 2021, Aurinia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN).
LUPKYNIS was the first FDA-approved oral therapy for LN which causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death.
Tags:
Source: Aurinia Pharmaceuticals
Credit: